Verve Therapeutics | Editing out cardiovascular disease, VERV-101 and VERV-102

We are developing two product candidates targeting PCSK9 – VERVE-101 and VERVE-102. These single-course treatments are designed to permanently turn off the PCSK9 gene in the liver to reduce disease-driving LDL-C.

Ultimately, we plan to further expand to all adults at risk for ASCVD in the general population as a preventative measure.